Search Results - "Cheung, Kit Wun Kathy"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models by Sane, Rucha, Cheung, Kit Wun Kathy, Kovács, Péter, Farasyn, Taleah, Li, Ruina, Bui, Annamaria, Musib, Luna, Kis, Emese, Plise, Emile, Gáborik, Zsuzsanna

    Published in Drug metabolism and disposition (01-12-2020)
    “…Organic anion-transporting polypeptide (OATP) 1B1/3-mediated drug-drug interaction (DDI) potential is evaluated in vivo with rosuvastatin (RST) as a probe…”
    Get full text
    Journal Article
  2. 2

    Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters by Cheung, Kit Wun Kathy, Groen, Bianca D., Burckart, Gilbert J., Zhang, Lei, Wildt, Saskia N., Huang, Shiew‐Mei

    Published in Journal of clinical pharmacology (01-09-2019)
    “…Developmental changes in the biological processes involved in the disposition of drugs, such as membrane transporter expression and activity, may alter the…”
    Get full text
    Journal Article
  3. 3

    Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model by Jing, Jing, Chen, Yuan, Musib, Luna, Jin, Jin Y., Cheung, Kit Wun Kathy, Yoshida, Kenta, Sane, Rucha

    Published in Cancer chemotherapy and pharmacology (01-05-2022)
    “…Purpose Ipatasertib, a potent and highly selective small-molecule inhibitor of AKT, is currently under investigation for treatment of cancer. Ipatasertib is a…”
    Get full text
    Journal Article
  4. 4

    Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform by Uguen, Marianne, Hilton, Magalie, Farid-Kapadia, Mufiza, Datye, Asim, Chohan, Saibah, Carlucci, Claudia, Dixon, Mark, Elze, Markus, Chen, Yingjia, Cheung, Kit Wun Kathy, Sane, Rucha, Zheng, Maoxia, Choi, YounJeong

    Published in Journal of biopharmaceutical statistics (02-11-2023)
    “…With the development of novel treatment therapies as well as evolving and innovative approaches to conduct clinical trials, the landscape of pediatric oncology…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics by Cheung, Kit Wun Kathy, Tang, Yang, Anders, Doreen, Barata, Teresa, Scalori, Astrid, Agarwal, Priya, Sane, Rucha, Cheeti, Sravanthi

    Published in Pharmaceutics (01-04-2024)
    “…Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection ( ) fusion-positive non-small cell lung cancer…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics by Cheeti, Sravanthi, Deng, Yuzhong, Chang, Ilsung, Georgescu, Isabela, Templeton, Ian, Choong, Nicholas, Cheung, Kit Wun Kathy, Girish, Sandhya, Musib, Luna

    Published in Clinical pharmacology in drug development (01-02-2021)
    “…Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF…”
    Get full text
    Journal Article
  9. 9

    Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling by Hunt, J. Porter, Dubinsky, Samuel, McKnite, Autumn M., Cheung, Kit Wun Kathy, Groen, Bianca D., Giacomini, Kathleen M., Wildt, Saskia N., Edginton, Andrea N., Watt, Kevin M.

    “…Optimal treatment of infants with many renally cleared drugs must account for maturational differences in renal transporter (RT) activity. Pediatric…”
    Get full text
    Journal Article
  10. 10

    Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects by Sane, Rucha S, Cheung, Kit Wun Kathy, Cho, Eunpi, Liederer, Bianca M, Hanover, Justin, Malhi, Vikram, Plise, Emile, Wong, Susan, Musib, Luna

    “…Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720),…”
    Get full text
    Journal Article
  11. 11

    GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study by Cheung, Kit Wun Kathy, Yoshida, Kenta, Cheeti, Sravanthi, Chen, Buyun, Morley, Roland, Chan, Iris T, Sahasranaman, Srikumar, Liu, Lichuan

    Published in Drug metabolism and disposition (01-09-2019)
    “…GDC-0810 (Cheeti et al., 2018) is an orally bioavailable, selective estrogen receptor (ER) degrader developed to treat ER-positive breast cancer. A…”
    Get full text
    Journal Article
  12. 12
  13. 13

    The Effect of Uremic Solutes on the Organic Cation Transporter 2 by Cheung, Kit Wun Kathy, Hsueh, Chia-Hsiang, Zhao, Ping, Meyer, Timothy W, Zhang, Lei, Huang, Shiew-Mei, Giacomini, Kathleen M

    Published in Journal of pharmaceutical sciences (01-09-2017)
    “…Chronic kidney disease (CKD) is characterized by the accumulation of uremic solutes; however, little is known about how these solutes affect drug absorption…”
    Get more information
    Journal Article
  14. 14
  15. 15